汉防己甲素联合屈洛昔芬对K562细胞bcr/abl表达的影响  

Effect of Tetrandrine Combined with Droloxifen on the Expression of bcr/abl of K562 at both mRNA and Protein levels

作　　者：陈宝安[1] 钱习军[1] 程坚[1] 高峰[1] 

机构地区：[1]东南大学附属中大医院血液科,南京210009

出　　处：《中国实验血液学杂志》2005年第1期95-99,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金资助;编号 :3 9970 83 2

摘　　要：为了研究汉防己甲素 (Tet)联合屈洛昔芬 (DRL)对K5 6 2细胞株凋亡相关因子bcr ablmRNA及蛋白表达的影响 ,Tet(1μmol L)和DRL(5 μmol L)单用及联合应用于K5 6 2细胞一定时间后 ,分别采用逆转录聚合酶链反应(RT PCR)和Westernblot方法检测K5 6 2细胞bcr ablmRNA和蛋白表达的变化。结果表明 :Tet和DRL单独应用对K5 6 2细胞bcr ablmRNA及蛋白表达均无影响 ,两药联合应用于 4 8小时K5 6 2细胞bcr ablmRNA表达开始下调 ,K5 6 2细胞P2 1 0 BCR ABL蛋白表达于 72小时开始下调。结论 :Tet和DRL联合应用可下调K5 6 2细胞bcr abl的表达 ,这可能是两药联用逆转耐药的机制之一。To observe the effect of Tetrandrine (tet) combined with Droloxifen (DRL) on the expression of bcr/abl mRNA and P 210 BCR/ABL protein of K562 cell line, after K562 cells were cultured in the medium containing Tet (1 μmol/L)、DRL(5 μmol/L) separately or in their combination for some time, the changes of bcr/abl mRNA and protein expression were detected by RT-PCR and Western blot respectively. The results showed that the application of single drug of Tet or DRL had no effect on bcr/abl mRNA and BCR/ABL protein expression in K562 cell line. However, Tet in combination with DRL began to downregulate bcr/abl mRNA and P 210 BCR/ABL expression of K562 cells at 48 h and 72 h, respectively. It is concluded that tetrandrine in combination with Droloxifen can downregulate the expression of bcr/abl mRNA and P 210 BCR/ABL protein and the combination may be involved in the mechanism underlying the reverse effects on multidrug resistance in leukemia.

关 键 词：汉防己甲素 屈洛昔芬 BCR/ABL基因 P^210BCR/ABL蛋白 K562细胞 

分 类 号：R733.7[医药卫生—肿瘤] R979.1[医药卫生—临床医学]